A new long-term study suggests that Omvoh (mirikizumab), a treatment for ulcerative colitis, may help patients maintain remission for up to four years, marking a major advancement in managing the chronic inflammatory bowel disease.

Long-Term Relief in Ulcerative Colitis

Ulcerative colitis, a type of inflammatory bowel disease (IBD), causes inflammation in the colon and leads to symptoms such as abdominal pain, fatigue, diarrhea, and bowel urgency.
While treatment options — including corticosteroids, biologics, and immunomodulators — can help manage the condition, there is currently no cure, and many patients eventually lose response to existing therapies.

Findings from the LUCENT-3 study, recently presented at United European Gastroenterology (UEG) Week, indicate that patients treated with Omvoh (mirikizumab) achieved durable, long-term remission and improvements in quality of life.

Study Findings: 78% Achieved Long-Term Clinical Remission

The LUCENT-3 trial followed participants from earlier LUCENT-1 and LUCENT-2 studies, which first evaluated the safety and efficacy of mirikizumab in 1,279 adults with moderate to severe ulcerative colitis.
Over the course of four years, researchers found that 78% of participants who achieved clinical remission after one year of treatment maintained both corticosteroid-free remission and long-term disease control after four years.

Additionally:

• 93% of patients reported at least a 3-point reduction in bowel urgency (Urgency Numeric Rating Scale).
• 74% achieved minimal urgency symptoms (score of 0 or 1).
• 81% sustained endoscopic remission, showing significant healing of the intestinal lining.

“These findings demonstrate the high likelihood of durability of clinical remission with mirikizumab treatment,” said Dr. Bruce Sands, lead investigator and Professor of Medicine at the Icahn School of Medicine at Mount Sinai. “This gives patients and physicians confidence that once remission is achieved, it’s likely to be sustained over time.”

How Omvoh Works

Mirikizumab is a monoclonal antibody that targets interleukin-23 (IL-23) — a key cytokine involved in triggering and amplifying inflammation in ulcerative colitis.
By selectively blocking IL-23, Omvoh helps reduce intestinal inflammation and promote mucosal healing.

The U.S. Food and Drug Administration (FDA) approved Omvoh in 2023 for adults with moderately to severely active ulcerative colitis, marking a new class of IL-23 inhibitors in gastrointestinal therapeutics.

Experts Highlight Importance of Long-Term Data

Experts emphasize that such long-term results are vital for chronic diseases like ulcerative colitis, where patients require lifelong management.

“Most initial clinical trials assess results for only up to one year,” said Dr. Ashwin N. Ananthakrishnan, Director of the Crohn’s and Colitis Center at Massachusetts General Hospital, who was not involved in the study.
“For lifelong conditions, it’s critical to understand both the long-term efficacy and safety of new treatments.”

He noted that around 20% of patients show no initial response to therapy, and 30–40% lose response over time, underscoring the need for effective and sustainable treatment options.

A Step Forward for Ulcerative Colitis Management

Dr. Rudolph Bedford, a gastroenterologist at Providence Saint John’s Health Center, also praised the findings:
“It’s encouraging to see long-term data proving both the drug’s efficacy and tolerability. Ulcerative colitis significantly impacts patients’ quality of life, and durable remission over four years is an important milestone.”

Although the LUCENT-3 results have not yet been published in a peer-reviewed journal, the findings represent a promising step toward sustained disease control in ulcerative colitis.

Source: Medical News Today – “New ulcerative colitis drug Omvoh linked to sustained remission after 4 years”